Loading clinical trials...
Loading clinical trials...
A 2-part, Open Label, Phase 1 Study to Investigate the Pharmacokinetics, Safety and Tolerability of Two Different Amlitelimab Drug Products After Administration of a Single Subcutaneous Dose in Healthy Adult Participants
Conditions
Interventions
Amlitelimab DP1
Amlitelimab DP2
Locations
1
United States
Clinical Pharmacology of Miami-Site Number: 8400001
Hialeah, Florida, United States
Start Date
April 28, 2022
Primary Completion Date
May 22, 2023
Completion Date
May 22, 2023
Last Updated
September 19, 2025
NCT07310264
NCT06342713
NCT07472361
NCT06823947
NCT06649110
NCT07240675
Lead Sponsor
Sanofi
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions